“…Some of them are new molecules as Meroxest, a synthetic merosesquiterpene derivative of the trans -communic acid, plentiful in Cupressus sempervirens [ 176 ], or Jadomycin, which is synthesized by the bacteria Streptomyces venezuelae [ 177 ]. Other compounds are part of the current therapeutic repertoire, like oxaliplatin [ 178 ], bleomycin [ 179 ], gemcitabine [ 180 , 181 ], cyclophosphamide [ 182 ], celecoxib [ 183 ], capecitabine [ 184 , 185 ], bortezomib (a proteasome inhibitor, approved for the treatment of multiple myeloma) [ 186 , 187 ], and arsenic trioxide (ATO). ATO, which is used in the treatment of acute promyelocytic leukemia (APL), can produce a loss of permeability of the outer mitochondrial membrane and impair the function of the respiratory chain, leading to an increase in superoxide anion [ 188 – 191 ].…”